

# Mattias F Lindberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7053724/publications.pdf>

Version: 2024-02-01

13  
papers

500  
citations

933447

10  
h-index

1125743

13  
g-index

16  
all docs

16  
docs citations

16  
times ranked

954  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. <i>Nature Communications</i> , 2017, 8, 707.	12.8	123
2	HER2 CART Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. <i>Cancer Research</i> , 2019, 79, 899-904.	0.9	84
3	A retro-inverso cell-penetrating peptide for siRNA delivery. <i>Journal of Nanobiotechnology</i> , 2017, 15, 34.	9.1	55
4	The gene transfection properties of a lipophosphoramidate derivative with two phytanyl chains. <i>Biomaterials</i> , 2012, 33, 6240-6253.	11.4	40
5	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFN $\gamma$ Signaling. <i>Cancer Research</i> , 2017, 77, 4562-4566.	0.9	39
6	A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. <i>Cell Death and Disease</i> , 2018, 9, 810.	6.3	38
7	Optimisation of vectorisation property: A comparative study for a secondary amphipathic peptide. <i>International Journal of Pharmaceutics</i> , 2016, 509, 71-84.	5.2	31
8	Efficient in vivo transfection and safety profile of a CpG-free and codon optimized luciferase plasmid using a cationic lipophosphoramidate in a multiple intravenous administration procedure. <i>Biomaterials</i> , 2015, 59, 1-11.	11.4	30
9	Lipothiophosphoramidates for gene delivery: critical role of the cationic polar headgroup. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 2051.	2.8	20
10	BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. <i>Cell Death and Disease</i> , 2017, 8, e2982-e2982.	6.3	17
11	Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary. <i>JCO Precision Oncology</i> , 2018, 2, 1-25.	3.0	10
12	Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma. <i>Melanoma Research</i> , 2022, 32, 241-248.	1.2	9
13	Small molecule inhibitors and a kinase-dead expressing mouse model demonstrate that the kinase activity of Chk1 is essential for mouse embryos and cancer cells. <i>Life Science Alliance</i> , 2020, 3, e202000671.	2.8	4